Anna Tomczyk
Partner | New York
Anna Tomczyk

Anna Tomczyk advises companies, financial institutions and investment product sponsors on capital raising, securities regulation and strategic transactions. Her practice spans equity and debt capital markets, with particular experience in life sciences, digital assets and exchange-traded products (ETPs). 

Ms. Tomczyk represents issuers, underwriters and placement agents in initial public offerings, follow-on offerings, confidentially marketed public offerings, at-the-market financings, registered direct offerings, PIPE and Rule 144A and Regulation S offerings. She works with U.S. and international companies at every stage of development, from preparing for an IPO or initial listing through subsequent financings and ongoing public company obligations. 

A significant part of Ms. Tomczyk’s practice focuses on crypt asset and commodity ETPs.  She advises sponsors on product structuring, Securities Act registration, SEC review, exchange listing, launch and ongoing disclosure obligations, including spot and multi-asset products.  She also counsels clients on securities law and disclosure questions arising from evolving digital asset markets and product features. 

Ms. Tomczyk has substantial experience advising biotechnology, pharmaceutical and medical device companies, as well as the investment banks that serve them. She helps clients evaluate financing alternatives, execute capital markets transactions and address the disclosure and regulatory issues associated with clinical development, commercialization and access to the U.S. public markets. She serves as an ongoing advisor to public companies and their boards on SEC reporting, corporate governance, stock exchange requirements, shareholder matters and securities law compliance. Her practice also encompasses public mergers and acquisitions, financial restructurings, liability management and other strategic transactions.

Ms. Tomczyk is recognized by The Legal 500 US for her work in debt, equity, global and high-yield capital markets offerings.

  • Morgan Stanley, on the launch of their Bitcoin, Ethereum and Solana ETPs.
  • Femasys Inc., a clinical-stage medical device company, in its $30 million private placement of common stock and warrants.
  • Aquestive Therapeutics, a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, in its US$85 million underwritten offering.
  • Select Medical Holdings Corporation, a leading operator of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers, and Concentra Group Holdings Parent, Inc., a wholly owned subsidiary of Select Medical, in connection with Concentra’s IPO.
  • 21Shares and ARK Invest on the launch of their first Bitcoin ETP
  • 21Shares on the launch of their Ethereum, Solana, XRP, Dogecoin, Polkadot, Sui, and Hyperliquid ETPs.
  • Aquestive Therapeutics, a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, in its US$75 million CMPO.
  • Femasys Inc., a clinical-stage medical device company, in its initial public offering.
  • The ad hoc group of secured and unsecured bondholders of Brazil’s largest domestic airline, GOL Linhas Aéreas Inteligentes S.A., in connection with its US$1.6 billion combined liability management and new capital financing transaction.
  • TAG Holdings Limited in its SPAC business combination with AGBA Acquisition Limited 
  • BioAtla, Inc. (Nasdaq: “BCAB”) in its US$189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers).
  • VIA optronics AG, a leading supplier of enhanced display solutions, in its US$93.75 million cross- border initial public offering and listing on the NYSE.
  • Acacia Research Corporation (Nasdaq: "ACTG") in connection with its strategic partnership with Starboard Value, consisting of a financing providing Acacia with access to up to US$400 million of new capital for strategic investments and acquisitions.
  • B&G Foods in connection with its registered public offering of US$550 million in aggregate principal amount of 5.25% senior notes due 2027.
  • Zyla Life Sciences in its merger with Assertio Therapeutics, Inc.
  • Sales Agents in multiple At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
  • OraSure Technologies, Inc. in its US$95 million public offering of common stock.
  • The underwriters in connection with Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD)’s US$25 million public offering of common stock.
  • Cowen and Company, as underwriter, in the US$97 million initial public offering of Boston Omaha Corporation.
  • Minerva Neurosciences Inc. in its US$32 million initial public offering.
  • Piper Jaffray, as managing underwriter, in the US$40 million initial public offering of Tengion Inc.
  • Cowen and Company, as lead underwriter, in a US$55 million follow-on offering for TherapeuticsMD, Inc.
  • Cowen and Company, as lead underwriter, in US$15 million and US$30 million follow-on offerings for Trillium Therapeutics.
  • Cowen and Company, as sales agent, in at-the-market offerings for Amicus Therapeutics, Boston Omaha Corporation, Kempharm Inc., and Trillium Therapeutics Inc.
  • Stifel, Nicolaus & Company, as lead underwriter, in a US$30 million follow-on offering for TherapeuticsMD, Inc.
  • RBC Capital Markets LLC, as lead underwriter, in a US$25 million follow-on offering for Kempharm Inc.
  • RBC Capital Markets LLC, as sales agent, in an at-the-market offering for Kempharm Inc.
  • The initial purchasers in a US$225 million offering of convertible senior notes for Amicus Therapeutics.
  • Anterios Inc. on its sale to Allergan.
  • A fishing supply company in its US$330 million high yield note offering.
  • Rexnord Corporation, in its US$500 million high yield note offering.
  • A mass customization conglomerate in its US$400 million senior note offering.
  • The underwriters, including Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley, UBS and Wells Fargo, in follow-on offerings of common stock and preferred stock of numerous international shipping and oil & gas companies, including Baltic Trading, Box Ships, Costamare, Dryships, Excel Maritime, GasLog, Ocean Rig, Safe Bulkers and Scorpio Bulkers.
  • Jefferies, on securities law aspects of its US$10 billion merger of equals with Leucadia National Corporation.

Includes matters handled at Dechert or prior to joining the firm.

  • Capital Raising and Asset Monetization Strategies for Life Sciences Companies — 2025 Life Sciences Day, Philadelphia, PA (March 5, 2025)
Services Industries
    • University of Rochester, B.A., 2005
    • Fordham University School of Law, J.D., 2008
    • New York
    • Member, Capital Markets Editorial Advisory Board for 2023, Law360

Related News & Insights

Resources relating to Anna Tomczyk